Tafenoquine — FDA meeting
In Q4 2026
In Q4 2026, the Company will seek a meeting with FDA to discuss data requirements for a potential sNDA following the NCT0627370 interim analysis (regardless of outcome)Source filing
SXTP biotech catalysts & pipeline
60 DEGREES PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
Arakoda — NDA/BLA submission
2027
Arakoda NDA for babesiosis planned for 2027, pending outcome of clinical trial program; FDA orphan drug status granted in 2024Source filing